GLIOTEM 100MG CAP

About

Gliotem (Temozolomide) is an oral alkylating agent primarily used in the treatment of glioblastoma multiforme and anaplastic astrocytoma, aggressive forms of brain cancer. As a prodrug, temozolomide is rapidly converted at physiological pH to its active metabolite, MTIC (5-(3-methyl-1-triazen-1-yl)imidazole-4-carboxamide). This active metabolite then methylates DNA at specific sites, leading to DNA damage and ultimately triggering apoptosis (programmed cell death) in tumor cells. Its ability to cross the blood-brain barrier makes it particularly effective for central nervous system malignancies. Temozolomide is often used in combination with radiation therapy, especially in newly diagnosed glioblastoma, to enhance therapeutic outcomes and improve patient survival.

Uses

• Newly diagnosed glioblastoma multiforme.
• Refractory anaplastic astrocytoma.
• Malignant melanoma (off-label in some cases).
• Other high-grade brain tumors.

Directions For Use

Take on an empty stomach, preferably at bedtime, to help reduce nausea and vomiting.

Benefits

• Oral administration for patient convenience.
• Crosses the blood-brain barrier effectively.
• Proven efficacy in certain brain tumors.
• Often used synergistically with radiation therapy.
• Improves progression-free and overall survival.
• Well-established treatment for glioblastoma.

Side Effects

• Nausea
• Vomiting
• Fatigue
• Headache
• Constipation
• Alopecia (hair loss)
• Myelosuppression (low blood counts)
• Rash
• Anorexia
• Dizziness
• Opportunistic infections
• Liver enzyme elevation

Safety Measures

• Alcohol - Avoid or limit alcohol due to potential for increased nausea, vomiting, and liver toxicity.
• Pregnancy - Contraindicated; highly teratogenic and causes fetal harm. Use effective contraception during and after treatment.
• Breastfeeding - Contraindicated; potential for serious adverse effects in the infant. Discontinue breastfeeding.
• Liver - Use with caution; dose adjustment may be needed in patients with severe hepatic impairment.
• Kidney - Use with caution; dose adjustment may be needed in patients with severe renal impairment.
• Lung - Monitor for pulmonary toxicity, though less common than with some other chemotherapies; report any new respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.